Altimmune Q3 net loss $0.39/sh; cash $140.8M; obesity trial readout Q4 2023

Altimmune, Inc.

2023-Q3 EPS reported -$1.10 revenue$389,000

Net loss $20.7M ($0.39/sh) vs $23.5M ($0.48) in Q3 2022.
Cash, equivalents & short-term investments $140.8M as of Sep 30, 2023.
Top-line 48-week MOMENTUM Phase 2 obesity trial data expected Q4 2023; 391 subjects randomized.
HepTcell Phase 2 CHB top-line results anticipated Q1 2024; ~80 subjects enrolled.
Pemvidutide granted Fast Track for NASH; IMPACT Phase 2b enrollment ongoing; results Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Altimmune, Inc. reported the three months ended September 30, 2023 results: net income $20.7 million, or $0.39 net loss per share, EPS $0.39 net loss per share.

Period: the three months ended September 30, 2023
Net income: $20.7 million, or $0.39 net loss per share
EPS: $0.39 net loss per share
Result: reported results

Exact text from the filing

Net loss for the three months ended September 30, 2023 was $20.7 million, or $0.39 net loss per share, compared to a net loss of $23.5 million, or $0.48 net loss per share, in the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-23-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.